Blockade of hERG K+ channel by antimalarial drug, primaquine

Archives of Pharmacal Research

Volumn 33, Issue 5, 2010, Pages 769-773

  Kim, Ki Suk ^a   Lee, Hyang Ae ^a   Cha, Shin Woo ^a   Kwon, Myung Sang ^b   Kim, Eun Joo ^a  

^a Korea Research Institute of Chemical Technology   (South Korea)

^b Kangwon National University   (South Korea)

Author keywords

hERG; Pore region mutants; Primaquine; S6 residue hERG mutants

Indexed keywords

ALANINE; ANTIMALARIAL AGENT; DELAYED RECTIFIER POTASSIUM CHANNEL; PHENYLALANINE; POTASSIUM CHANNEL HERG; PRIMAQUINE; SERINE; SIBUTRAMINE; THREONINE; TYROSINE;

ANTIMALARIAL ACTIVITY; ARTICLE; CELL LINE; CONTROLLED STUDY; DOSE RESPONSE; DRUG INHIBITION; ELECTRIC POTENTIAL; HUMAN; HUMAN CELL; IC 50; ION CURRENT; MOLECULAR GENETICS; MUTANT; PROTEIN EXPRESSION; REPOLARIZATION; WILD TYPE;

ANTIMALARIALS; CELL LINE; DOSE-RESPONSE RELATIONSHIP, DRUG; ETHER-A-GO-GO POTASSIUM CHANNELS; HUMANS; MUTAGENESIS, SITE-DIRECTED; PATCH-CLAMP TECHNIQUES; PRIMAQUINE; TIME FACTORS;

EID: 77954476443     PISSN: 02536269     EISSN: 19763786     Source Type: Journal    
DOI: 10.1007/s12272-010-0517-6     Document Type: Article

References (17)

1. K. N. Bangchang W. Songsaeng A. Thanavibul P. Choroenlarp J. Karbwang 1994 Pharmacokinetics of primaquine in G6PD deficient and G6PD normal patients with vivax malaria Trans. R. Soc. Trop. Med. Hyg. 88 220 222 10.1016/0035-9203(94)90306-9 1:STN:280:DyaK2czhtVKntg%3D%3D 8036681 (Pubitemid 24139696)
2. S. W. Bass M. A. Ramirez D. M. Aviado 1972 Cardiopulmonary effects of antimalarial drugs. VI. Adenosine, quinacrine and primaquine Toxicol. Appl. Pharmacol. 21 464 481 10.1016/0041-008X(72)90004-X 1:CAS:528:DyaE38XktFCju7w%3D 5047047
3. M. E. Curran I. Splawski K. W. Timothy G. M. Vincent E. D. Green M. T. Keating 1995 A molecular basis for cardiac arrhythmia: hERG mutations cause long QT syndrome Cell 80 795 803 10.1016/0092-8674(95)90358-5 1:CAS:528: DyaK2MXksVahsL4%3D 7889573
4. A. A. Grace A. J. Camm 1998 Quinidine N. Engl. J. Med. 338 35 45 10.1056/NEJM199801013380107 1:CAS:528:DyaK1cXltVyitQ%3D%3D 9414330 (Pubitemid 28040538)
5. G. Iglesias-cubero J. J. Rodriguez-reguero J. M. Rojo-ortega 1993 Restrictive cardiomyopathy caused by chloroquine Br. Heart J. 69 451 452 10.1136/hrt.69.5.451 1:STN:280:DyaK3s3pvVCqsA%3D%3D 8518071
6. J. P. Lees-Miller Y. Duan G. Q. Teng H. J. Duff 2000 Molecular determinant of high-affinity dofetilide binding to hERG1 expressed in Xenopus oocytes: involvement of S6 sites Mol. Pharmacol. 57 367 374 1:CAS:528: DC%2BD3cXhtVakt7g%3D 10648647
7. J. S. Mitcheson J. Chen M. Lin C. Culberson M. C. Sanguinetti 2000 A structural basis for drug-induced long QT syndrome Proc. Natl. Acad. Sci. U S A 97 12329 12333 10.1073/pnas.210244497 1:CAS:528:DC%2BD3cXnvVSnsro%3D 11005845
8. G. Orta-Salazar R. A. Bouchard F. Morales-Salgado E. M. Salinas-Stefanon 2002 Inhibition of cardiac Na+ current by primaquine Br. J. Pharmacol. 135 751 763 10.1038/sj.bjp.0704460 1:CAS:528:DC%2BD38XhvVejsbk%3D 11834623
9. R. C. Owens Jr. T. D. Nolin 2006 Antimicrobial-associated QT interval prolongation: pointes of interest Clin. Infect. Dis. 43 1603 1611 10.1086/508873 1:CAS:528:DC%2BD2sXislWjsw%3D%3D 17109296 (Pubitemid 44910994)
10. W. Redfern L. Carlsson A. Davis W. Lynch I. MacKenzie S. Palethorpe P. Siegl I. Strang A. Sullivan R. Wallis A. Camm T. Hammond 2003 Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development Cardiovasc. Res. 58 32 45 10.1016/S0008- 6363(02)00846-5 1:CAS:528:DC%2BD3sXit12gsb8%3D 12667944 (Pubitemid 36351620)
11. M. C. Sanguinetti N. K. Jurkiewicz 1990 Two components of cardiac delayed rectifier K+ current. Differential sensitivity to block by class III antiarrhythmic agents J. Gen. Physiol. 96 195 215 10.1085/jgp.96.1.195 1:CAS:528:DyaK3cXls1Gitbo%3D 2170562 (Pubitemid 20227082)
12. M. C. Sanguinetti 1999 Dysfunction of delayed rectifier potassium channels in an inherited cardiac arrhythmia Ann. N. Y. Acad. Sci. 868 406 413 10.1111/j.1749-6632.1999.tb11302.x 1:CAS:528:DyaK1MXjvFKitb0%3D 10414310 (Pubitemid 29281141)
13. R. R. Shah 2005 Drugs, QTc interval prolongation and final ICH E14 guideline: an important milestone with challenges ahead Drug Saf. 28 1009 1028 10.2165/00002018-200528110-00003 1:CAS:528:DC%2BD2MXhtlWhtb%2FP 16231954 (Pubitemid 41483706)
14. P. S. Spector M. E. Curran M. T. Keating 1996 Class III antiarrhymic drugs block hERG, a human cardiac delayed rectifier K+ channel. Open-channel block by methanesulfonanilides Circ. Res. 78 499 503 1:CAS:528: DyaK28XhtlWrt7Y%3D 8593709
15. L. Tona Y. -C. H. NG T. Akera T. M. Brody 1990 Depressant effects of chlorquine on the isolated guinea-pig heart Eur. J. Pharmacol. 178 293 301 10.1016/0014-2999(90)90108-I 1:CAS:528:DyaK3cXktVSiu7c%3D 2340863
16. K. F. Wenckebach 1923 Cinchona derivatives in the treatment of heart disorders JAMA 81 472 474
17. H. J. Witchel J. C. Hanconx 2000 Familial and acquired long QT syndrome and the cardiac rapid delayed rectifier potassium current Clin. Exp. Pharmacol. Physiol. 27 753 766 10.1046/j.1440-1681.2000.03337.x 1:CAS:528: DC%2BD3cXntValsLc%3D 11022966